Aptorum Group Shareholders Approve Merger with DiamiR Biosciences and Corporate Domestication

On June 9, 2026, Aptorum Group Limited held an Extraordinary General Meeting (EGM) where shareholders overwhelmingly approved all proposals related to its proposed merger with DiamiR Biosciences Corp. Key approvals included the merger itself, a share consolidation (reverse split) at a ratio between 2-1 and 10-1, the domestication of the company from the Cayman Islands to Delaware, and the issuance of common stock representing more than 20% of outstanding shares to DiamiR stockholders. Additionally, shareholders approved a new stock incentive plan and the appointment of five directors to the post-merger board. DiamiR shareholders also approved the transaction on the same day. Following the domestication, DiamiR will become a wholly owned subsidiary of the Delaware-incorporated Aptorum. The all-stock merger, originally announced in July 2025, remains subject to customary closing conditions. The companies anticipate the transaction will close before fiscal 2027. This merger combines Aptorum's clinical-stage biopharmaceutical assets with DiamiR's blood-based diagnostic platform for brain health.